Federal Contractor Profile
Amgen INC.
Federal contracting record: $1.1B obligated across 19 awards from 3 agencies, FY 2016–2026.
$1.1B
Total Obligated
19
Award Records
3
Agencies Served
3
NAICS Codes
Company Profile
Parent UEI (Unique Entity Identifier)
D92HARF1LKA9
CAGE Code
0JVZ6
Registered Entities (UEIs)
3 under this organization
Address
1 AMGEN CENTER DR, THOUSAND OAKS, CA, 913201799
First Federal Award
Oct 13, 2015
Most Recent Award
Sep 8, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$1.1B
100.0% of total obligations
- Department of Veterans Affairs$140K
0.0% of total obligations
- Department of Justice$13K
0.0% of total obligations
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Aug 4, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN. | $66M |
| Mar 6, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN. | $60M |
| Sep 4, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO | $2.3M |
| Jul 15, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN. | $90M |
| Sep 18, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN. | $129M |
| Aug 8, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENDOR MANAGED INVENTORY (VMI) SERVICES FOR USG PROCURED 165,906 DOSES OF NEULASTA PRODUCT TO MITIGATE INJURIES CAUSED BY EXPOSURE TO CHEMICAL, BIOLOGICAL THREAT AGENTS, PHYSICAL, RADIOLOGIC AND NUCLEAR EXPOSURES. | $274K |
| Mar 12, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENDOR MANAGED INVENTORY (VMI) SERVICES FOR USG PROCURED 165,906 DOSES OF NEULASTA PRODUCT TO MITIGATE INJURIES CAUSED BY EXPOSURE TO CHEMICAL, BIOLOGICAL THREAT AGENTS, PHYSICAL, RADIOLOGIC AND NUCLEAR EXPOSURES. | $580K |
| Oct 1, 2023 | Department of Veterans Affairs260-NETWORK CONTRACT OFFICE 20 (36C260) | 325412 | TAVNEOS (AVACOPAN) | $129K |
| Sep 20, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN. | $205M |
| Sep 7, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 325414 | RTOR NUMBER: RTOR-CSF-0004 MAINTENANCE OF PREVIOUSLY PURCHASED COLONY STIMULATING FACTOR(S) (G- OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION | $66K → |
| Sep 7, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 325414 | IGF::OT::IGF RTOR NUMBER: RTOR-CSF-0005 ACQUISITION OF COLONY STIMULATING FACTOR(S) (G-CSF OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION | $50K |
| Aug 22, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 325412 | NPLATE ADMINISTRATION KIT DEVELOPMENT FOR THE TREATMENT OF APPROVED INDICATIONS, INCLUDING ACUTE RADIATION SYNDROME (ARS) | $7.3M |
| Sep 28, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN. | $290M |
| Jul 20, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO | $475K |
| Jan 31, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO | $2.2M |
| Sep 13, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 325414 | RTOR NUMBER: RTOR-CSF-0004 MAINTENANCE OF PREVIOUSLY PURCHASED COLONY STIMULATING FACTOR(S) (G- OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION | $49K → |
| Apr 1, 2021 | Department of Veterans Affairs245-NETWORK CONTRACT OFFICE 5 (36C245) | 325412 | AFLURIA QUADRIVALENT 0.5ML SINGLE-DOSE, PRE-FILLED QUADRIVALENT SYRINGES DESIGNATED FOR PERSONS 36 MONTHS AND OLDER PKG OF 10, NDC: 33332-0321-01 | $75K |
| Mar 31, 2021 | Department of JusticeFCI TERMINAL ISLAND | 325412 | TO PROVIDE FLU SHOTS FOR FY 2021 FOR STAFF AT THE FEDERAL CORRECTIONAL INSTITUTION TERMINAL ISLAND, CA. | $8K |
| Mar 31, 2021 | Department of JusticeFCI TERMINAL ISLAND | 325412 | TO PROVIDE FLU SHOTS FOR FY 2021 FOR STAFF AT THE FEDERAL CORRECTIONAL INSTITUTION TERMINAL ISLAND, CA. | $3K |
| Mar 31, 2021 | Department of JusticeFCI TERMINAL ISLAND | 325412 | TO PROVIDE FLU SHOTS FOR FY 2021 FOR STAFF AT THE FEDERAL CORRECTIONAL INSTITUTION TERMINAL ISLAND, CA. | $3K |
| Sep 26, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO | $21M |
| Sep 13, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 325414 | IGF::OT::IGF RTOR NUMBER: RTOR-CSF-0005 ACQUISITION OF COLONY STIMULATING FACTOR(S) (G-CSF OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION | $154M |
| Aug 20, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 325414 | RTOR NUMBER: RTOR-CSF-0004 MAINTENANCE OF PREVIOUSLY PURCHASED COLONY STIMULATING FACTOR(S) (G- OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION | $542K → |
| Sep 30, 2016 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 325414 | IGF::OT::IGF FOR OTHER FUNCTIONS PROJECT: ACQUISITION OF COLONY STIMULATING FACTOR(S) (G-CSF OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION (RTOR-CSF-0003) | $38M |
Want to win work like Amgen INC.?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.